Suggested remit: To appraise the clinical and cost-effectiveness of catumaxomab within its marketing authorisation for treating malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6580
Provisional Schedule
- Committee meeting:
- 10 June 2026
- Expected publication:
- 30 September 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Warwick Evidence, Warwick Medical School, University of Warwick
Stakeholders
- Companies sponsors
- Pharmanovia (catumaxomab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- AMMF – The Cholangiocarcinoma Charity
- Breast Cancer Now
- Ovarian Cancer Action
- Prostate Cancer Research
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Pathologists
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 October 2025 | Invitation to participate |
| 02 October 2025 | To appraise the clinical and cost effectiveness of Catumaxomab within its marketing authorisation for treating malignant ascites ID6580 |
| 25 July 2025 - 22 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6580 |
| 25 July 2025 | In progress. Scoping commencing |
| 15 May 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual